Genentech finally came through with its long-expected rejection of Roche's acquisition bid, saying that the asking price "substantially undervalues the company," according to this story in the New York Times. Analysts predict that the companies will continue to negotiate, and that Roche will raise the offer from its original $43.7 billion.